stockrow
Friday 6 November 2026
Export AMWL’s income statement to Excel — free account
American Well Corporation
AMWL Healthcare Health Information Services
American Well Corporation’s revenue for fiscal 2025 (year ended December 2025) was $249.3 million, down 1.98% from fiscal 2024.
- Revenue
- −13.0%
- EPS
- +67.9%
- Free cash flow
- +22.0%
Quarter to September 2026, against a year earlier
11.94
0.17
−1.40%
Follow AMWL
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.10 | 0.70 | 0.37 | 0.32 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(19.86) | 14.26 | (88.77) | (4.54) | |
P/B ratio |
1.03 | 0.65 | 0.36 | 0.32 | |
Price to Tangible BV |
1.36 | 0.86 | 0.49 | 0.43 | |
EV/Sales |
0.24 | (0.20) | (0.39) | (0.42) | |
EV/EBITDA |
0.00 | 0.96 | 1.68 | 1.53 | |
EV/Operating CF |
(2.60) | 1.66 | 2.22 | 1.57 | |
EV/FCF |
(1.79) | 1.37 | 2.08 | 1.57 | |
Quick Ratio |
2.85 | 2.73 | 2.83 | 3.17 | |
Current Ratio |
3.01 | 2.90 | 3.09 | 3.37 | |
Net Debt/EBITDA |
31.78 | 110.10 | 19.74 | 11.60 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.63 | 0.61 | 0.64 | 0.66 | |
Operating CF/Net income |
1.03 | (1.08) | 0.09 | 0.70 | |
Capex/Depreciation |
(0.50) | (0.37) | (0.34) | 0.00 | |
Research and Development Expense of Revenue |
19.59% | 19.89% | 22.56% | 25.20% | |
Selling, General and Administrative Expense of Revenue |
46.49% | 37.94% | 46.36% | 56.15% | |
Intangible Assets out of Total Assets |
0.18 | 0.17 | 0.19 | 0.20 | |
Share Based Compensation of Revenue |
4.76% | 3.91% | 4.20% | 8.28% | |
Graham Net Nets |
0.71 | 1.12 | 1.98 | 2.17 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(25.13%) | (52.30%) | (103.04%) | (121.18%) | |
Free Cash Flow Yield |
(12.05%) | (20.96%) | (51.14%) | (83.73%) | |
Revenue per Share |
2.87 | 3.11 | 3.31 | 3.45 | |
Operating CF per Share |
(0.68) | 0.64 | (0.06) | (1.08) | |
Capex per Share |
(0.17) | (0.17) | (0.17) | 0.00 | |
Free Cash Flow per Share |
(0.86) | 0.47 | (0.23) | (1.08) | |
Cash per Share |
10.64 | 11.74 | 10.85 | 11.36 | |
Shareholders Equity per Share |
13.20 | 13.98 | 14.47 | 15.44 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
13.20 | 13.98 | 14.47 | 15.44 | |
Free Cash Flow |
(14.64) | 7.86 | (3.77) | (17.37) | |
Working Capital |
166.60 | 173.43 | 175.28 | 173.47 | |
Capital Expenditures |
(2.97) | (2.86) | (2.79) | (0.01) | |
Net Current Asset Value |
165.26 | 171.82 | 173.21 | 170.68 | |
EV/EBIT |
0.00 | 0.54 | 1.00 | 0.98 | |
Capex to Sales |
0.06 | 0.05 | 0.05 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
55.03 | 53.08 | 64.55 | 60.79 | |
Average Payables |
4.90 | 2.71 | 3.91 | 3.33 | |
Average Inventory |
1.36 | 1.57 | 1.84 | 2.02 | |
Average Assets |
334.32 | 357.92 | 372.72 | 379.88 | |
Average Common Equity |
246.26 | 264.44 | 272.95 | 282.02 |
Columns are period end dates · fundamentals updated 5 Nov 2026